The emergence of a T790M missense mutation is commonly associated with acquired resistance to first-generation EGFR inhibitors in NSCLC [8], and is detected in a subpopulation of cells in some tumors even before treatment with an EGFR inhibitor [25]. Here, EGFR is linked to non-small cell lung carcinoma.